To require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill provides demonstration project to increase access to biosimilar biological products under the Medicare program Beginning not later than 1 year after the date of the enactment of this Act, the Secretary of Health. It relies on definition changes, appropriations, reporting requirements, and compliance mandates. The main policy areas are Healthcare Consumers and Healthcare.
Who Benefits and How
Public beneficiaries or protected communities affected by the clause could see lower costs.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties and Patients and health care consumers affected by the bill could lose revenue opportunities.
Key Provisions
- Provides demonstration project to increase access to biosimilar biological products under the Medicare program Beginning not later than 1 year after the date of the enactment of this Act, the Secretary of Health...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill provides demonstration project to increase access to biosimilar biological products under the Medicare program Beginning not later than 1 year after the date of the enactment of this Act, the Secretary of Health.
Key Policy Areas
Healthcare Consumers, Healthcare
Primary Purpose
The bill provides demonstration project to increase access to biosimilar biological products under the Medicare program Beginning not later than 1 year after the date of the enactment of this Act, the Secretary of Health.
Policy Domains
Whole bill
Identified Gains
- Public beneficiaries or protected communities affected by the clause
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
- Patients and health care consumers affected by the bill
Legislative Progress
IntroducedMr. Hudson introduced the following bill; which was referred to …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology